Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 35 Life Science Startup Investors in Belgium

Last updated: Apr 2024 A list of 35 angel investors and VC funds that invest in Life science startups based in Belgium. We rank investors based on the number of investments they made in Life science companies from Belgium. We update this investor list every month.

Top 35 Life Science Startup Investors in Belgium

Investor	Life Science Belgium investments
PMV	6
Meusinvest (Noshaq)	4
S.R.I.W.	3
Limburgse Reconversie Maatschappij	3
Sambrinvest	3
Qbic Fund	3
Theodorus III	3
Pierre Drion	2
SFPI-FPIM	2
Innovation Fund	2
New Science Ventures	2
Annie Vereecken	2
Luc Vauterin	2
Innovation Industries	1
VIB	1
OBI SA	1
Capricorn Partners	1
Kenneth Buckfire	1
Nausicaa Ventures	1
the SRIW Life Sciences	1
V-Bio Ventures	1
Ifoghas Investments	1
6K Venture Capital	1
Fonds Vives II (University of Louvain, UCL)	1
European Investment Bank	1
Korys	1
Fund+	1
Merieux Developpement	1
Smedvig	1
UCB Ventures	1
Opdorp Finance BVBA	1
Newton Biocapital	1
Mérieux Equity Partners	1
Nivelinvest	1
Seventure Partners	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Do and dare company

Investment focus

Software, Biotechnology, Health Care
Seed, Series A, Funding Round
Belgium, The Netherlands, United States

Portfolio highlights

IVEX — IVEX offers Repeatable and Scalable Testing & Validation Data Analytics solutions for ADAS/AD Vehicles.
Funkey — Kies je teambuilding uit meer dan 500 onvergetelijke activiteiten. Wij zorgen voor de volledige organisatie, incl. eventuele catering en overnachting.
dScribe — Welcome to the most intuitive data catalog on the planet

Noshaq offers financial services to help businesses develop.

Investment focus

Health Care, Biotechnology, Medical
Seed, Series A, Funding Round
Belgium, France, Germany

Portfolio highlights

Samabriva — Biotechnology company that has developed an automated, proprietary bioproduction system available to companies who want to produce high-value molecules.
Raw Stadia — Raw Stadia is a sports technology company that specializes in surface player interactions.
HEPHAISTOS-Pharma — Hephaistos Pharma is a developing weapons firm. They provide services for oncology, immunotherapy, and cancer. An online inquiry form is available on the company's website.

The S.R.I.W. Group is an institution at the heart of the financial market that assists entrepreneurs in creating and developing businesses in the Walloon region. It reflects the effort of Wallonian industry in facing the challenges of the creation of economic value in the 21st century. Since its creation in 1979, the SociÃ©tÃ© RÃ©gionaledâ€™Investissement de Wallonie has continuously been expanding its abilities to adapt and anticipate as well as its flexibility in order to meet the requirements of its partners who are confronted with the evolution of the world economy. The principles of good governance, a strong business culture and shared values at the heart of the Group constitute important assets to capture the changing realities of the market and progress in a sustainable development perspective.

Investment focus

Biotechnology, Health Care, Manufacturing
Funding Round, Series A, Series B
Belgium, United States, Spain

Portfolio highlights

Univercells — Univercells delivers novel biomanufacturing platforms and solutions aiming at making biologics available & affordable to all.
Intressa Vascular — Intressa Vascular provides innovative solutions to address life-threatening cardiovascular conditions such as aortic dissection.
Santero Therapeutics — Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance. Santero develops antimicrobials with novel modes of action to combat the rise of antibiotic-resistant microorganisms.

Oxygen for growth - LRM

Investment focus

Information Technology, Software, Biotechnology
Funding Round, Series A, Seed
Belgium, United States, The Netherlands

Portfolio highlights

Cumul.io — Create powerful dashboards in minutes. Share with your teams, or integrate in your platform. Drive growth in your business today!
MobieTrain — Unlock the potential of your customer-facing employees and create memorable customer experiences with MobieTrain's app.
Raw Stadia — Raw Stadia is a sports technology company that specializes in surface player interactions.

Sambrinvest is an active venture capital player in the region of Charleroi - Thuin.

Investment focus

Biotechnology, Health Care, Information Technology
Seed, Series A, Series B
Belgium, France, Spain

Portfolio highlights

cikisi — Specialized in Web Intelligence (collecting, searching and filtering web information). Help companies and organizations to take advantage of Web information that are relevant to their development. Develops and commercializes Cikisi WMT, a Web Intelligence Solution.
AbolerIS Pharma — AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance.
Santero Therapeutics — Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance. Santero develops antimicrobials with novel modes of action to combat the rise of antibiotic-resistant microorganisms.

The Qbic Fund is a multi-sector fund supporting spin-off companies of the Ghent, Brussels and Antwerp university associations and of VITO. Through its strategic partnership with the universities of Ghent, Brussels and Antwerp, and VITO, the Qbic Fund has early and privileged access to promising research projects at these partner universities. Ourinvestment approach is based on early in-depth and independent review and analysis followed by hands on involvement and support.In May 2012 the Qbic Fund held its first close and currently it has over € 30 million under management. The Qbic Fund is backed by several public and private investors and managed by Qbic Venture Partners.

Investment focus

Biotechnology, Software, Health Care
Seed, Funding Round, Series A
Belgium

Portfolio highlights

VoxelSensors — Novel sensor architecture designed for low latency and low power 3D perception.
Morrow Optics — Looking for the next big thing in eyewear technology? Check out Morrow's electrified progressives, also known as autofocals! These innovative glasses switch focus length with a touch of button, providing you with seamless vision from near to far. Learn more about this technology on Morrow's website.
Swave Photonics — Swave develops Spatial Computing, Holography, holographic chips, and holograms in the HXR chip to create 3D augmented and virtual reality and HUD Heads Up Displays

Theodorus is the spin-off fund of Université Libre de Bruxelles that invests ininvest in early stage projects based on proprietary disruptive technologies.

Investment focus

Health Care, Life Science, Medical
Funding Round, Seed, Series A
Belgium, Canada, France

Portfolio highlights

DrugBank — DrugBank augments human intelligence to improve the world’s health. Our suite of products are powered by the world’s most complete and up-to-date pharmaceutical knowledge database. It includes everything there is to know about drugs and how they work in the body. We enable companies to improve healthcare delivery through precision medicine orclinical software applications, as well as uncover insights through data science in drug discovery. Our knowledge base can be integrated into software solutions to help achieve clinical intelligence. Companies can easily scale their usage through our API and launch faster with flexible data modules. By providing users with advanced insights and the right information at the right time, users are empowered to make better health decisions.Our extensive, structured datasets are used to discover novel drug candidates, identify drug repurposing opportunities, and build predictive machine learning models. Companies working with data science can find answers quickly and get drugs to market faster with our evidence-based drug information. Lastly, our publicly available resource, DrugBank Online, is free-to-use with limited datasets available for download for academic and non-commercial researchers. DrugBank has been cited in over 13,000 academic publications and is used by millions of researchers and health professionals globally.
HypnoVR — HypnoVR is a virtual reality software for anesthesia, treatment of pain, and anxiety. It was founded in 2016 and is based in Strasbourg, France.
Cascador Health — Cascador Health bridges the gap between sources and users of healthcare data. Using curated, validated and anonymized RWD allows healthcare providers and life science industry to gain insights and provide better care.

Pierre Drion - CEO @ Petercam

Investment focus

Biotechnology, Health Care, Life Science
Series A, Series B, Funding Round
Belgium

Portfolio highlights

A-Mansia Biotech — A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
Santero Therapeutics — Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance. Santero develops antimicrobials with novel modes of action to combat the rise of antibiotic-resistant microorganisms.

The Federal Holding and Investment Company (SFPI-FPIM) centrally manages the federal government’s shareholdings, cooperates with the government on specific projects and pursues its own investment policy in the interests of the Belgian economy.

Investment focus

Health Care, Biotechnology, Medical Device
Funding Round, Series B, Series A
Belgium, United States, France

Portfolio highlights

Cohabs — We create sustainable & community-driven shared homes around the world for young workers and interns. Join our community.
Univercells — Univercells delivers novel biomanufacturing platforms and solutions aiming at making biologics available & affordable to all.
Tangent Works — Create predictive models in seconds for faster and better forecasting & anomaly detection with TIM InstantML.

Chemical, Advanced Materials, Cosmetics, Recycling, CleanTech, Plastics and Rubber Manufacturing, Nanotechnology, Biosciences

Investment focus

Health Care, Manufacturing, Information Technology
Funding Round, Seed, Series A
Belgium, France, Luxembourg

Portfolio highlights

Aloxy — Aloxy offers reliable IIot solutions tailored to the needs of the process industry. Our valve sensor provides an open and close indication of manual valves.
Graftys — Graftys, an Aix-en-Provence, France-based early stage company focused on advanced bone biologics.
SENSE in — SENSE in manufactures monitoring solutions based on thermomechanical sensors sensitive to deformation, pressure, temperature, humidity, and more. Their solutions evaluate in real time or periodically the expected characteristics and alert on abnormal behavior, threshold overruns, and damage.

New Science Ventures is a venture capital firm that focuses on investments in life sciences and information technology companies. They invest in early and late stage companies taking novel scientific approaches to address significant unmet needs, while creating order-of-magnitude improvements in performances. The company also invests in companiesusing science-based innovations to address market needs in life sciences such as pharmaceuticals, biologics, medical devices, diagnostics, and IT. The team of the company expertise in strategy and corporate planning, operations and cost management, and leadership development.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series D
United States, United Kingdom, Belgium

Portfolio highlights

Glydways — A revolution in better mobility and public transportation.
Paragraf — We Work to Develop Innovative and Useful End Products from Novel Materials. Our Analogue Sensors Are Designed to Provide Accurate Field Gradient Mapping & Alignment.
Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.

Annie Vereecken

Investment focus

Biotechnology, Medical, Hospital
Seed, Series A, Funding Round
Belgium

Portfolio highlights

Ziphius — Ziphius Vaccines is a biopharmaceutical company dedicated to developing next-generation vaccines for the prevention of infectious diseases.
Sensolus — Introducing our smart, industrial-grade tracking solution. With battery life of up to ten years, and no additional infrastructure needed.
Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).

Luc Vauterin - Board Member @ ONTOFORCE

Investment focus

Life Science, Data Integration, Data Visualization
Seed, Series A
Belgium

Portfolio highlights

ONTOFORCE — ONTOFORCE creates and implements pioneering semantic search technology for information management. Our user-friendly data search platform DISQOVER builds uniquely intelligent links between heterogeneous data sources, allowing everybody to become a data scientist.

Innovation Industries is a Dutch venture capital fund investing in impactful deep tech, focusing on sustainability, scalability, and ESG-aligned companies.

Investment focus

Semiconductor, Health Care, Manufacturing
Funding Round, Seed, Series B
The Netherlands, Belgium, United States

Portfolio highlights

CarbonX — CarbonX develops and supplies new materials to design the next generation of materials.
Microsure — Microsurgery is characterized by performing surgery close to the limits of what is physically possible. It has designed a motion stabilizer system, which is designed by and for microsurgeons who want to overcome their physical limitations and enhance their performance. The Microsure motion stabilizer system has improved the quality of microsurgicalprocedures and makes it easier to perform, with the objective to increase the number of treatment options for patients.The extraordinary control and precision offered by the Microsure motion stabilizer provides better and more constant surgical outcome and allows the development of new highly accurate surgical procedures that are currently unavailable. The Microsure system has already been successfully used in a first clinical trial with 8 micro-surgical operations for lymphedema in the Maastricht UMC+. With our investment, Microsure will accelerate the market introduction and sales of its systems.Microsure was founded in 2014 and is headquartered in Eindhoven, The Netherlands.
Onera Health — Introduction to Onera sleep diagnostics and monitoring solutions

Strategic research in on life sciences and biotechnology

Investment focus

Biotechnology, Pharmaceutical, Health Care
Series A, Funding Round, Seed
Belgium, Brazil, Denmark

Portfolio highlights

Animab — Animal Health Company
Aphea.Bio — Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptakeof nutrients from the soil.
Muna Therapeutics — Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.

OBI SA

Investment focus

Life Science, Biotechnology, Health Diagnostics
Funding Round
Belgium

Portfolio highlights

Diagenode — Diagenode is an international life sciences company that develops and commercializes innovative instruments and reagents systems for life science research and molecular diagnostics. Founded in 2003 in Liege (Belgium), Diagenode is a global company, with headquarters in Liege, Belgium and Sparta, NJ, USA. Diagenode also has a local sales office inthe United Kingdom to better serve this specific country.Diagenode's customers include leading epigenetics researchers, academic institutions, high-profile genome centers and core labs, life sciences tools companies, molecular diagnostics players, and pharmaceutical and biotechnology companies.Epigenetics Division

Capricorn Partners is a unique independent manager of venture capital, growth capital and quoted equity funds

Investment focus

Biotechnology, Health Care, Software
Funding Round, Series B, Series A
Belgium, United States, The Netherlands

Portfolio highlights

Chainels — The tenant experience app for every property in your portfolio. Save time, gain insights and collaborate with your tenants all in one place.
VoxelSensors — Novel sensor architecture designed for low latency and low power 3D perception.
Electric Hydrogen — Electric Hydrogen designs and builds low-cost, high-efficiency green hydrogen systems to economically decarbonize industrial sectors like ammonia and steel

Kenneth Buckfire is the Chief Executive Officer at Miller Buckfire.

Investment focus

Medical, Health Care, Life Science
Series A
Belgium

Portfolio highlights

Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.

A multi-industry early stage venture capital fund Nausicaa Ventures is an early stage investment fund organisation focused on investment rounds between EUR 1 and 4 million. Nausicaa Ventures was created in 2009 by bringing together 35 private investors and selected institutional investors, such as the European Investment Fund or ING Bank, under the management of ...

Investment focus

Software, CRM, Big Data
Series B, Funding Round
Belgium

Portfolio highlights

NGDATA — Unleash the potential of your customer data. Our AI-driven Intelligent Engagement Platform helps you create intelligent customer journeys and meaningful digital experiences.
Ovizio — Optimize your process, control your CPPs & monitor quality while reducing hands-on time and risk of contamination.

the SRIW Life Sciences

Investment focus

Biotechnology, Medical, Biopharma
Series A, Series B
Belgium

Portfolio highlights

A-Mansia Biotech — A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.

V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Seed
Belgium, France, United Kingdom

Portfolio highlights

AstriVax — AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline.
Precirix — Developing radio-immunotherapeutic drugs for cancer patients.
Sibylla Biotech — Sibylla Biotech developed small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas.

Ifoghas Investments operates as an investment firm.

Investment focus

Medical, Health Care, Life Science
Series A
Belgium

Portfolio highlights

Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.

6K Venture Capital operates as a venture capital firm.

Investment focus

Medical, Software, Health Care
Seed, Series A
Panama, Belgium

Portfolio highlights

Rise Of Defenders — Rise of Defenders is a very interesting Metaverse NFT game, you can use your creativity and tactical thinking to become an excellent player and receive extremely attractive rewards.
Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.

Fonds Vives II (University of Louvain, UCL)

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Seed
Belgium, United States

Portfolio highlights

Virovet — Antiviral drugs and thermostable vaccines for livestock
Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
ITeos Therapeutics — iTeos Therapeutics is pioneering the discovery and development of highly differentiated immuno-oncology therapeutics for cancer patients.

European Investment Bank (EIB) provides lending, borrowing, and treasury services primarily in the European Union.The company offers project loans for the public and private sectors; loans to banks and other intermediaries; structured finance products; guarantees and securitization instruments for senior and subordinated debts; project bonds;equity and fund investment products such as infrastructure equity and debt funds, and environmental funds; and venture capital funds and security packages for funds.The company also offers microfinance; risk sharing finance for research, development, and innovation projects; finance and technical expertise for sustainable energy projects; infrastructure project advisory services; support for urban development projects; guarantees for transport infrastructure; and funding for public-private partnerships and small- and medium-sized enterprises.EIB serves the transportation, global loans, energy, industry, health, education, water, sewerage, infrastructure, services, telecommunications, agriculture, and fisheries sectors.European Investment Bank was founded in 1958 and is based in Luxembourg.

Investment focus

Biotechnology, Health Care, Software
Debt Financing, Post-IPO Debt, Funding Round
France, Germany, The Netherlands

Portfolio highlights

Eldrive — The largest charging point operator in Eastern Europe | Our network is expanding rapidly yet our focus is fixed on renewables, for a greener future. We provide AC & DC charging across Bulgaria, Romania and Lithuania.
ABN AMRO Bank — Als bank leggen wij de focus op inclusiviteit, duurzaamheid, sociaal ondernemen, innovatie, dagelijkse bankzaken en meer.
Enel Green Power — Enel Green Power is the company that deals with renewable energy from every perspective: from direct sales through PPA, to commitment at the forefront with its plants worldwide.

Korys is the name chosen by the Colruyt family for their investment structure. The name Korys is derived from the Latin word for hazelnut tree – Corylus - which is at the origin of the Colruyt name.Their multi-disciplinary approach enables us to create a well-balanced, diversified portfolio of listed stocks and bonds, private equity funds, anddirect participations in small and medium-sized companies. Through their investments, they aim to make a positive impact on people and the planet, while generating attractive returns. A “three P” approach (People, Planet, Profit) forms the cornerstone of their investment strategy. They invest for the long term, as they realize that it takes time to achieve the sustainable impact they are aiming for. They focus their investments in sectors in which they have built substantial expertise as a team: Cleantech, consumer goods & retail and life sciences.

Investment focus

Biotechnology, Information Technology, E-Commerce
Series A, Series B, Series C
Belgium, The Netherlands, India

Portfolio highlights

Ampacimon — Ampacimon develops dynamic line rating systems for transmission and distribution systems operators. Ampacimon’s products address grid infrastructure challenges such as aging assets, transmissions congestion, renewable integration, interconnectors.
Aphea.Bio — Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptakeof nutrients from the soil.
Sahyadri Farms — Sahyadri Farms is a farmer producer and agricultural company.

Fund+ is a venture capital firm that invests in companies operating in the diagnostics, therapeutics, medical devices, and life science sectors. The firm wants to create sustainable shareholders' value, contribute to the development of a leadership position in the life sciences sector, and generate a tangible, beneficial societal impact.Fund+ was established in 2015 and is based in Leuven, Belgium.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
Belgium, United States, Spain

Portfolio highlights

AstriVax — AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline.
Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Mérieux Développement is specialized in Growth and Venture capital transactions in the healthcare and nutrition sectors. We support companies with products or services offering true differentiation and capacity to create substantial value over the long term. Our investment team, based in Europe and North America, brings its expertise andinternational network to help entrepreneurs disrupt and grasp substantial market opportunities. Mérieux Développement is an affiliate of Institut Mérieux, which employs approximately 17,000 employees worldwide, with consolidated revenues exceeding 2.5 billion Euros in 2017.

Investment focus

Health Care, Biotechnology, Medical Device
Funding Round, Series C, Series B
France, United States, Belgium

Portfolio highlights

SeqOne Genomics — Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGShas had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.
TISSIUM — TISSIUM is creating the future of tissue reconstruction. Learn more about our novel solutions based on our proprietary platform of biomorphic programmable polymers.
Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.

Venture Capital firm based in London. We help enable business funding though capital investment. In turn, that funds and drives business growth as exceptional speed. Visit our site to find out how our proven model of business investment can help your start up.

Investment focus

Medical, Health Care, Life Science
Series A
Belgium

Portfolio highlights

Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.

UCB Ventures is a €150 million strategic corporate venture fund

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Funding Round
United States, Belgium, Spain

Portfolio highlights

Splice Bio — We are working with our proprietary platform to address key limitations of current gene therapy approaches to treat patients in need.
Switch Therapeutics — Switch Therapeutics is a biotech company dedicated to revolutionizing RNA interference (RNAi) therapies with conditionally activated siRNAs (CASi).
Code Biotherapeutics — Code Biotherapeutics is an emerging next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases not well served by other gene therapy technologies.

Opdorp Finance BVBA

Investment focus

Life Science, Data Integration, Data Visualization
Series A
Belgium

Portfolio highlights

ONTOFORCE — ONTOFORCE creates and implements pioneering semantic search technology for information management. Our user-friendly data search platform DISQOVER builds uniquely intelligent links between heterogeneous data sources, allowing everybody to become a data scientist.

Our mission is to mature innovation and support the growth of our portfolio companies to create value for patients, society, local ecosystems, and investors.

Investment focus

Biotechnology, Medical, Health Care
Series A, Funding Round, Seed
Belgium, Japan, France

Portfolio highlights

AdipoPharma — By harnessing the power of the Adipocyte AdipoPharma is committed to developing innovative treatment for type 2 diabetes
AbolerIS Pharma — AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance.
Santero Therapeutics — Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance. Santero develops antimicrobials with novel modes of action to combat the rise of antibiotic-resistant microorganisms.

Mérieux Equity Partners (“MxEP”) is a management company dedicated to venture, growth and LBO investments in the healthcare and nutrition sectors. MxEP actively supports entrepreneurs and industrial companies with differentiated products and services, by providing privileged access to its expertise and international network. MxEP currently managesmore than €600m AUM and has recently launched a new vehicle MP3 of €350m dedicated to growth/LBO.

Investment focus

Biotechnology, Health Care, Medical
Series A, Private Equity, Funding Round
France, Sweden, Belgium

Portfolio highlights

Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Mablink Bioscience — Mablink Bioscience is a biotechnology company specialized in the development of a new class of cancer drugs, called Antibody Drug Conjugate (ADC).
Broken String Biosciences — Our platform accelerates the characterisation of novel gene editing technologies to unlock the next wave of cell & gene therapies.

Nivelinvest is a venture capital firm based in Belgium that finances seed stage investments of Small and Medium Enterprises.

Investment focus

Biotechnology, iOS, Construction
Series A, Seed, Funding Round
Belgium, United States

Portfolio highlights

CluePoints — CluePoints' Risk-Based Quality Management (RBQM) Software illuminates risks that could compromise patient safety, and enables compliance with ICH E6 (R2).
A-Mansia Biotech — A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.

Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.

Investment focus

Biotechnology, Health Care, Software
Series A, Funding Round, Series B
France, United States, Germany

Portfolio highlights

Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
Allozymes — Allozymes, Pte. Ltd. is a leading deep technology company applying innovative ultrahigh-throughput microfluidics technology to accelerate enzyme evolution and development. We developed sensitive, accurate, and generic assays for the detection of enzymatic reactions, proprietary microfluidic chips and proteomics technologies to take enzymedevelopment to the next level.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Investors by industry

Media (entertainment)

EdTech

Consumer

Climate